Dataset Information

Identification of methylglyoxal reactive proteins with photocaged glycating agents

ABSTRACT: Abstract Methylglyoxal is a highly reactive metabolite that is formed spontaneously in the glycolytic pathway. The side chains of various amino acid residues react with methylglyoxal to form advanced-glycation end products (AGEs). This enzyme-independent process introduces post-translational modifications (PTMs) onto the proteins and it was long thought that the resulting AGEs primarily inhibited proteins. More recent studies have shown that these AGEs can act in signaling and feedback loops. Moreover, it was shown that a large number of proteins react reversibly with methylglyoxal. These findings led to a renewed interest in methylglyoxal induced AGEs and led to the development of novel tools and methodologies that can be used to identify the modified proteins. Many of studies are nowadays still performed by adding methylglyoxal exogenously, often in a high concentration, despite the high reactivity of methylglyoxal. We here report new photocaged-methylglyoxal derivatives that allow the direct release of methylglyoxal in the sample of interest at the desired time and experimental condition. We demonstrate that the methylglyoxal derivatives can be released in situ by irradiating the photocaged probe with UV light. Furthermore, we show that this approach is more efficient. A far larger number of proteins are labeled with the photocaged probes than with the chemically activated probes. The here reported approach should allow studying in situ glycation under physiological more relevant conditions.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Permanent Cell Line Cell

SUBMITTER: Horvatovich Péter

LAB HEAD: Peter Horvatovich

PROVIDER: PXD061990 | Pride | 2025-11-17

REPOSITORIES: Pride

ACCESS DATA

Dataset's files

Source:

Items per page:

1 - 5 of 75

Publications

Identification of Methylglyoxal Reactive Proteins with Photocaged Glycating Agents.

Sokoliova Saskia S Sardaru I Raluca IR Warguła Franciszek P FP Hermans Jos H JH Permentier Hjalmar P HP Horvatovich Peter L PL Witte Martin D MD

Chembiochem : a European journal of chemical biology 20250929 21

Methylglyoxal is a highly reactive metabolite that is formed spontaneously in the glycolytic pathway. The side chains of various amino acid residues react with methylglyoxal to form advanced-glycation end products (AGEs). This enzyme-independent process introduces post-translational modifications onto the proteins and it is long thought that the resulting AGEs primarily inhibit proteins. More recent studies have shown that these AGEs can act in signaling and feedback loops and that a large numbe ...[more]

PMID: 41017761

Similar Datasets

Project description:Proteomic modifications linked to non-enzymatic glycation and glycoxidation are common in all tissues under hyperglycemic conditions, as present in metabolic syndrome, type 2 diabetes (T2D), mice bearing a homozygous mutation in leptin (so-called Ob/Ob mice, a common model of obesity and T2D) and mice subjected to a high fat diet (HFD). It has been already shown that the circulating levels of glycated or glycoxidated proteins (e.g., glycated hemoglobin or albumin) are commonly employed as a reliable indicator of overall glycemic status. Albeit these initial non-enzymatic reactions are reversible, following a series of chemical rearrangements protein glycation and glycoxidation become irreversible, generating the so-called advanced glycation end-products (AGEs). AGEs are commonly detected in tissue proteins with an extended half-life, including dermal collagens as well as extracellular matrix proteins. In these proteins, Nϵ-carboxymethyllysine (CML), pentosidins, and glucosepane represent the most prevalent AGEs. As an additional, novel mechanism linking protein PTMs to altered immunity, the research presented herein highlights that several components of the MHC class II antigen processing and presentation machinery are glycated in metabolic conditions associated with increased oxidative stress, leading to qualitative and quantitative changes in the MHC class II immunopeptidome. To investigate the impact of T2D and metabolic syndrome on the proteome of antigen presenting cells (APCs) we isolated dendritic cells (DCs, which are key for the initiation of antigen-specific immunity) from the lymph nodes of Ob/Ob mice and syngeneic, age-matched control C57BL/6 (B6) mice and mapped the oxidized proteins at the molecular and cellular level by employing label-free mass spectrometry using at least three biologically independent whole lysates of DCs. Analysis of the type of post-translational modifications (PTMs) accumulated in the proteome from the combined three biological Ob/Ob samples ranked the formyl-lysine and site-specific carboxymethylation on lysine (CML) as the most abundant AGEs found in the glycated proteome; with CML having about two-fold increase in their total PTM-modified spectral counts in the Ob/Ob vs control dendritic cell proteome. Additional glycoxidation-specific PTMs, that mapped only on the Ob/Ob proteome, albeit at a smaller amount than CML and formyl lysine, were glyceryl lysine and 3-deoxyglucosone. Finally, a separate proteomic analysis, performed on gradient purified late endosomes also mapped an increased number of PTM-modified proteins in the Ob/Ob organelles. Ingenuity pathway analysis (IPA) analysis identified metabolic pathways as well as phagocytosis, antigen processing and presentation and phagosome maturation amongst the top pathways including a higher number of proteins modified by AGEs or carbonylation in primary DCs from Ob/Ob vs. control mice. The site-specific amide-AGE modifications that we detected also mapped to proteins involved in response to DC signaling, immune cell trafficking, actin and cytoskeleton signaling, cell movement, and carbohydrate, nucleic acids and protein metabolism. Overall, these findings indicate that the DC proteome of Ob/Ob mice has an increased number of carbonyl PTMs and AGEs as compared to DC of C57BL/6 mice. The results presented herein are one of the first to map the redox mediated PTM in the primary mouse DC in healthy vs T2DM type syndrome physiological conditions.

			Action	DRS
	22mdv045-sas345.mgf	Mgf
	22mdv045-sas345.raw	Raw
	479A1_220718204606.mgf	Mgf
	479A1_220718204606.raw	Raw
	479A1_220718204606_PXD.mzID	Mzid